If your child's physician has determined that a GLP-1 medication is appropriate, the conversation almost always narrows to two names: Wegovy and Saxenda. They are the only GLP-1 medications FDA-approved for adolescents ages 12 to 17, and while they work through the same hormone pathway, they differ in ways that matter for real families — how often they're injected, what the trials showed, how insurers treat them, and how they fit a teenager's actual life. This guide compares them honestly, then explains what changes the day your child turns 18.
The Short Version
Wegovy (semaglutide) is a once-weekly injection with the strongest adolescent trial results recorded for a GLP-1 [1]. Saxenda (liraglutide) is a once-daily injection with more modest trial results [2], but it has been approved for adolescents longer and is sometimes preferred by insurers or better tolerated by individual patients. Neither is "the best" in the abstract — the right choice depends on your child's health profile, coverage, and preferences, which is why this decision belongs in a physician's hands.
Side-by-Side Comparison
| Wegovy | Saxenda | |
|---|---|---|
| Active ingredient | Semaglutide 2.4 mg | Liraglutide 3 mg |
| FDA approval for ages 12–17 | December 2022 [3] | December 2020 [4] |
| How it's taken | Once-weekly injection | Once-daily injection |
| Key adolescent trial | STEP TEENS (NEJM 2022), 201 adolescents, 68 weeks [1] | NEJM 2020 liraglutide trial, 251 adolescents, 56 weeks [2] |
| Average result | 16.1% BMI reduction vs. +0.6% on placebo; 73% lost ≥5% body weight [1] | 4.6% BMI reduction difference vs. placebo; 43% lost ≥5% BMI vs. 19% on placebo [2] |
| Most common side effects | GI symptoms (nausea, vomiting, diarrhea) in 62% vs. 42% placebo, mostly mild-to-moderate [1] | GI symptoms in 65% vs. 37% placebo, mostly transient [2] |
| Injection burden per year | 52 injections | 365 injections |
| List price (2026, approx.) | ~$1,350/month before coverage or savings programs [5] | ~$1,350/month before coverage or savings programs [5] |
16.1%
Average BMI reduction among adolescents on once-weekly semaglutide (Wegovy) in the STEP TEENS trial — the strongest result recorded in an adolescent GLP-1 trial to date. Saxenda's adolescent trial showed meaningful but more modest results [1] [2].
What the Trial Numbers Mean in Practice
Numbers on a page flatten what these differences feel like day to day. The efficacy gap is real: semaglutide's adolescent results were substantially stronger than liraglutide's, which is why most clinical conversations start with Wegovy. But three practical factors regularly tip the decision the other way.
The first is insurance. Some plans cover one medication and not the other, or impose easier prior authorization requirements on one. Because prior authorization is where many families get stuck, a medication your plan actually covers can beat a theoretically stronger one you cannot access. This is work Thryvwell handles end-to-end for members — navigating coverage, prior authorization, and appeals — precisely because most families should not have to become insurance experts to get guideline-recommended care. The second is tolerability. Individual response varies; a teenager who struggles with side effects on one medication may do better on the other. The third is routine. A once-weekly injection is easier for most teenagers to sustain, but some families prefer the daily rhythm of Saxenda, and a dose that isn't taken doesn't work. There is no universal answer — there is the right answer for your child.
Key Takeaway
What Both Medications Require
Everything the two medications share matters more than what separates them. Both are approved only for adolescents with an initial BMI at or above the 95th percentile for age and sex [3] [4]. Both were studied — and should always be prescribed — alongside lifestyle and nutrition support, never as a standalone fix [1] [2]. Both involve gradual dose escalation to minimize side effects, active monitoring of growth and development, screening for disordered eating before starting, and a physician-guided plan for how long treatment should last. And both carry the same class-level cautions, including a boxed warning related to thyroid tumors observed in rodent studies and rare risks such as pancreatitis and gallstones [1] [2]. Our guides on side effects and growth monitoring cover both topics in depth.
Wondering if your teen qualifies?
Check Your Child's Eligibility →What Changes at 18
For families with an older teenager, it helps to know what is on the other side of that birthday, because the treatment landscape genuinely shifts.
The biggest change is that Zepbound (tirzepatide) becomes an option. Zepbound targets two hormone pathways rather than one and has produced the strongest adult weight management results of any approved medication, but it is approved for adults only — adolescent trials are still ongoing, and no one under 18 should use it outside a clinical trial [6]. At 18, it moves from off-limits to a legitimate part of the conversation with a physician.
Eligibility criteria also change: instead of BMI percentiles, adult thresholds apply (BMI of 30, or 27 with a weight-related condition). Insurance changes too, and often more disruptively — young adults move between a parent's plan, college insurance, and first-job coverage, each with different GLP-1 rules. And clinically, an 18 year old is usually managing appointments and refills alone for the first time, which is exactly when consistent follow-up tends to slip.
This transition is why Thryvwell treats ages 12 to 26 as one continuous span of care rather than two disconnected systems. A member who starts at 16 doesn't age out at 18 and start over with a new provider — the same care team carries them through the handoff, including any medication reassessment that the adult approvals open up.
Key Takeaway
Frequently Asked Questions
Which is better for teens, Wegovy or Saxenda?
Trial results favor Wegovy: 16.1% average BMI reduction versus more modest results for Saxenda [1] [2]. But "better" in practice depends on what your insurance covers, how your child tolerates the medication, and which routine they can sustain. Both are FDA-approved for ages 12 and up, and a physician should make the call with your family.
Can my teen switch from Saxenda to Wegovy?
Switching between GLP-1 medications is done in clinical practice, but it requires physician guidance on timing and dose equivalence. If coverage or tolerability is driving the question, raise it with your child's care team rather than making any change on your own.
Can a teenager take Zepbound?
No. Zepbound is approved for adults only, and adolescent trials are still under way [6]. A 17 year old should not use it outside a clinical trial; at 18 it becomes an option to discuss with a physician.
Do Wegovy and Saxenda cost the same?
List prices are similar — roughly $1,350 per month before insurance [5] — but out-of-pocket costs can differ dramatically depending on your plan's formulary, prior authorization rules, and manufacturer savings programs. Our guide to affording GLP-1 medications walks through every option.
Is Ozempic an option for my teenager?
No. Ozempic is approved for type 2 diabetes in adults, not for weight management in adolescents. Wegovy contains the same active ingredient (semaglutide) at the dose actually studied and approved for teens [3].
References
- Weghuber D, et al. Once-Weekly Semaglutide in Adolescents with Obesity (STEP TEENS). N Engl J Med. 2022;387(24):2245-2257.
- Kelly AS, et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med. 2020;382(22):2117-2128.
- U.S. Food and Drug Administration. Wegovy (semaglutide) Approval Letter for Chronic Weight Management in Pediatric Patients Aged 12 Years and Older. December 2022.
- Novo Nordisk. FDA Approves Saxenda (liraglutide) for the Treatment of Obesity in Adolescents Aged 12-17. December 2020.
- Novo Nordisk. Wegovy List Price and Savings Information. Accessed July 2026.
- Eli Lilly and Company. A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight. Clinical trial listing.
